Kalnisha Naidoo

Dr. Kalnisha Naidoo

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AHAndreas Heindl
Andreas Heindl
ISIvana Sestak
Ivana Sestak
KNKalnisha Naidoo
Kalnisha Naidoo
JCJack Cuzick
Jack Cuzick
MDMitchell Dowsett
Mitchell Dowsett
YYYinyin Yuan
Yinyin Yuan
Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptor–negative (ER-) subtype, the prognostic value of immune infiltration for ER+ disease is not well defined. Quantitative immune scores of cell abundance and spatial heterogeneity were computed using a fully automated hematoxylin and eosin–stained image analysis algorithm and spatial statistics for 1178 postmenopausal patients with ER+ breast cancer treated with five years’ tamoxifen or anastrozole. The prognostic significance of immune scores was compared with Oncotype DX 21-gene recurrence score (RS), PAM50 risk of recurrence (ROR) score, IHC4, and clinical treatment score, available for 963 patients. Statistical tests were two-sided. Scores of immune cell abundance were not associated with recurrence-free survival. In contrast, high immune spatial scores indicating increased cell spatial clustering were associated with poor 10-year, early (0–5 years), and late (5–10 years) recurrence-free survival (Immune Hotspot: LR-χ2 = 14.06, P < .001, for 0–10 years; LR-χ2 = 6.24, P = .01, for 0–5 years; LR-χ2 = 7.89, P = .005, for 5–10 years). The prognostic value of spatial scores for late recurrence was similar to that of IHC4 and RS in both populations, but was not as strong as other tests in comparison for recurrence across 10 years. These results provide a missing link between tumor immunity and disease outcome in ER+ disease by examining tumor spatial architecture. The association between spatial scores and late recurrence suggests a lasting memory of protumor immunity that may impact disease progression and evolution of endocrine treatment resistance, which may be exploited for therapeutic advances.

1 July 2019 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
PAPraneen Anand
Praneen Anand
EEEnas Elsafa
Enas Elsafa
RPRosario Privitera
Rosario Privitera
KNKalnisha Naidoo
Kalnisha Naidoo
YYYiangos Yiangou
Yiangos Yiangou
PMPeter Misra
Peter Misra
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) with associated chronic pain is a common and disabling condition. Current treatments for neuropathic pain in CIPN are largely ineffective, with unfavorable side-effects. The capsaicin 8% patch (capsaicin 179 mg patch) is approved for the treatment of neuropathic pain: a single topical cutaneous application can produce effective pain relief for up to 12 weeks. We assessed the therapeutic potential of capsaicin 8% patch in patients with painful CIPN, and its mechanism of action. Patients and methods: 16 patients with chronic painful CIPN (mean duration 2.5 years), in remission for cancer and not receiving chemotherapy, were treated with 30 min application of capsaicin 8% patch to the feet. Symptoms were monitored using the 11-point numerical pain rating scale (NPRS), and questionnaires. Investigations were performed at baseline and three months after patch application, including skin biopsies with a range of markers, and quantitative sensory testing (QST). Results: Patients reported significant reduction in spontaneous pain (mean NPRS: −1.27; 95% CI 0.2409 to 2.301; p=0.02), touch-evoked pain (−1.823; p=0.03) and cold-evoked pain (−1.456; p=0.03). Short-Form McGill questionnaire showed a reduction in neuropathic (p=0.0007), continuous (p=0.01) and overall pain (p=0.004); Patient Global Impression of Change showed improvement (p=0.001). Baseline skin biopsies showed loss of intra-epidermal nerve fibers (IENF), and also of sub-epidermal nerve fibers quantified by image analysis. Post-patch application skin biopsies showed a significant increase towards normalization of intra-epidermal and sub-epidermal nerve fibers (for IENF: structural marker PGP9.5, p=0.009; heat receptor TRPV1, p=0.027; regenerating nerve marker GAP43, p=0.04). Epidermal levels of Nerve Growth Factor (NGF), Neurotrophin-3 (NT-3), and Langerhans cells were also normalized. QST remained unchanged and there were no systemic side-effects, as in previous studies. Conclusion: Capsaicin 8% patch provides significant pain relief in CIPN, and may lead to regeneration and restoration of sensory nerve fibers ie, disease modification.

20 July 2018 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
SKSaira Khalique
Saira Khalique
KNKalnisha Naidoo
Kalnisha Naidoo
AAAyoma D. Attygalle
Ayoma D. Attygalle
DKDivya Kriplani
Divya Kriplani
FDFrances Daley
Frances Daley
RNRachael C. Natrajan
Rachael C. Natrajan
ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ARID1A defects. However, the accuracy of ARID1A immunohistochemistry (IHC) as a surrogate for mutation status has not fully been established for patient stratification in clinical trials. Here we tested whether ARID1A IHC could reliably predict ARID1A mutations identified by next‐generation sequencing. Three commercially available antibodies – EPR13501 (Abcam), D2A8U (Cell Signaling), and HPA005456 (Sigma) – were optimised for IHC using cell line models and human tissue, and screened across a cohort of 45 gynaecological tumours. IHC was scored independently by three pathologists using an immunoreactive score. ARID1A mutation status was assessed using two independent sequencing platforms and the concordance between ARID1A mutation and protein expression was evaluated using Receiver Operating Characteristic statistics. Overall, 21 ARID1A mutations were identified in 14/43 assessable tumours (33%), the majority of which were predicted to be deleterious. Mutations were identified in 6/17 (35%) ovarian clear cell carcinomas, 5/8 (63%) ovarian endometrioid carcinomas, 2/5 (40%) endometrial carcinomas, and 1/7 (14%) carcinosarcomas. ROC analysis identified greater than 95% concordance between mutation status and IHC using a modified immunoreactive score for all three antibodies allowing a definitive cut‐point for ARID1A mutant status to be calculated. Comprehensive assessment of concordance of ARID1A IHC and mutation status identified EPR13501 as an optimal antibody, with 100% concordance between ARID1A mutation status and protein expression, across different gynaecological histological subtypes. It delivered the best inter‐rater agreement between all pathologists, as well as a clear cost‐benefit advantage. This could allow patients to be accurately stratified based on their ARID1A IHC status into early phase clinical trials.

7 February 2017 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Open access
SRSara Reis
Sara Reis
PGPatrycja Gazinska
Patrycja Gazinska
JHJohn H. Hipwell
John H. Hipwell
TMThomy Mertzanidou
Thomy Mertzanidou
KNKalnisha Naidoo
Kalnisha Naidoo
DHDavid J. Hawkes
David J. Hawkes
Objective: The tumor microenvironment plays a crucial role in regulating tumor progression by a number of different mechanisms, in particular, the remodeling of collagen fibers in tumor-associated stroma, which has been reported to be related to patient survival. The underlying motivation of this work is that remodeling of collagen fibers gives rise to observable patterns in hematoxylin and eosin (H&E) stained slides from clinical cases of invasive breast carcinoma that the pathologist can label as mature or immature stroma. The aim of this paper is to categorise and automatically classify stromal regions according to their maturity and show that this classification agrees with that of skilled observers, hence providing a repeatable and quantitative measure for prognostic studies. Methods: We use multiscale basic image features and local binary patterns, in combination with a random decision trees classifier for classification of breast cancer stroma regions-of-interest (ROI). Results: We present results from a cohort of 55 patients with analysis of 169 ROI. Our multiscale approach achieved a classification accuracy of 84%. Conclusion: This work demonstrates the ability of texture-based image analysis to differentiate breast cancer stroma maturity in clinically acquired H&E-stained slides at least as well as skilled observers.

1 January 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KNKalnisha Naidoo
Kalnisha Naidoo
PWPatty T. Wai
Patty T. Wai
SMSarah L. Maguire
Sarah L. Maguire
FDFrances Daley
Frances Daley
SHSyed Haider
Syed Haider
RNRachael C. Natrajan
Rachael C. Natrajan
Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess the frequency and distribution of CDK12 protein expression by IHC in independent cohorts of breast cancer and correlate this with outcome and genomic status. We found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent, by IHC. CDK12 positivity correlated with HER2 positivity but was not an independent predictor of breast cancer–specific survival taking HER2 status into account; however, absent CDK12 protein expression significantly correlated with a triple-negative phenotype. Interestingly, CDK12 protein absence was associated with reduced expression of a number of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK, and γH2AX, suggesting a novel mechanism of CDK12-associated DDR dysregulation in breast cancer. Our data suggest that diagnostic IHC quantification of CDK12 in breast cancer is feasible, with CDK12 absence possibly signifying defective DDR function. This may have important therapeutic implications, particularly for triple-negative breast cancers. Mol Cancer Ther; 17(1); 306–15. ©2017 AACR.

14 November 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
KNKalnisha Naidoo
Kalnisha Naidoo
RJRichard Jones
Richard Jones
BDBranko Dmitrovic
Branko Dmitrovic
NWNilukshi Wijesuriya
Nilukshi Wijesuriya
Hemant M KocherHemant M Kocher
Hemant M Kocher
TCTatjana Crnogorac-Jurcevic
Tatjana Crnogorac-Jurcevic